Iarŭkova N, Chernev T, Nikolov A
Akush Ginekol (Sofiia). 1998;37(3):12-4.
A randomized clinical prospective study is carried out aiming to compare prophylaxis with Curosurf versus rescue treatment. 28 inborn VLBW I are included: 17 received Curosurf as prophylaxis and 11 controls, who received rescue treatment if indicated. Both groups are similar regarding mean body weight, mean gestational age, dosage of Curosurf, etc. Results underwent statistic analysis. Data from the study shows better effect from prophylaxis with Curosurf: smaller number of babies developed RDS and especially RDS grade III-IV (subsequently less babies needed a second dose of Curosurf); higher PaO2/FiO2 ratio; reduced duration of artificial ventilation and of oxygen therapy; reduced incidence of BPD. Results do not show statistically significant difference, but a tendency for ft. As a conclusion: prophylaxis with Curosurf leads to a decrease in the incidence and severity of RDS and to reduced duration of ventilation support and oxygen therapy.
开展了一项随机临床前瞻性研究,旨在比较珂立苏预防性用药与挽救性治疗的效果。纳入28例先天性极低出生体重儿:17例接受珂立苏预防性用药,11例为对照组,后者在有指征时接受挽救性治疗。两组在平均体重、平均胎龄、珂立苏剂量等方面相似。对结果进行了统计学分析。研究数据表明,珂立苏预防性用药效果更佳:发生呼吸窘迫综合征(RDS)尤其是III-IV级RDS的婴儿数量更少(随后需要第二剂珂立苏的婴儿也更少);动脉血氧分压/吸入氧浓度(PaO2/FiO2)比值更高;人工通气和氧疗持续时间缩短;支气管肺发育不良(BPD)发生率降低。结果虽未显示出统计学上的显著差异,但有这种趋势。结论:珂立苏预防性用药可降低RDS的发生率和严重程度,并缩短通气支持和氧疗的持续时间。